Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Replaces CEO, Plans to Spin Out Vilazodone Business

NEW YORK, May 15 (GenomeWeb News) - Clinical Data's board has approved plans to spin out the firm's investigational antidepressant drug vilazodone into a new company.

 

Clinical Data also said President and CEO Israel Stein has stepped down to become executive vice chairman. He will also serve as interim CFO, replacing Mark Shooman. Drew Fromkin, previously executive vice president of Clinical Data and president of the company's PGxHealth division, will now serve as president and CEO.

 

Clinical Data said it will spin out the vilazodone business to shareholders as a new company called Precigen Therapeutics. The new firm will develop the drug, as well as a potential companion biomarker test that will be developed by Clinical Data's PGxHealth division.

 

Clinical Data said it plans to issue the new company's shares to Clinical Data shareholders in the form of a tax-free stock dividend.

 

News of the spin out comes about two months after Clinical Data reorganized itself into three units: PGxHealth, Cogenics, and Vital Diagnostics.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.